clinical trial · NCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Eli Lilly and Company·phase1·completed·n = 46
OverweightLY3437943Ethinyl EstradiolDrospirenone
brief summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.
started
Sep 12, 2023
primary completion
Jul 11, 2024
completion
Jul 11, 2024
last updated
Jul 26, 2024
official title
A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol